logo
Share SHARE
FONT-SIZE Plus   Neg

Chelsea To Discuss NORTHERA NDA For Treatment Of Symptomatic Neurogenic OH

Chelsea Therapeutics International, Ltd. (CHTP) said it will meet with the Food and Drug Administration's, or FDA's, Cardiovascular and Renal Drugs Advisory Committee on February 23, 2012 to review clinical data in support of the New Drug Application, or NDA, for NORTHERA (droxidopa).

Chelsea is seeking approval of NORTHERA for treating symptomatic neurogenic orthostatic hypotension, or Neurogenic OH, in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

Dr. Simon Pedder, president and CEO of Chelsea, stated, "We have closely reviewed the materials prepared by the FDA, and look forward to presenting our clinical data to the Advisory Committee, which we believe will address the questions raised by the FDA. We believe that our clinical program has established robust safety and efficacy data for NORTHERA in this patient population."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Netflix has announced the new arrivals in its streaming video lineup in the month of December that include many Christmas-themed shows and films to choose from. The holiday season will also see some great movies disappearing from the platform. Shares of easyJet Plc were gaining around 6 percent in the morning trading in London after the airline reported higher revenues, traffic and capacity in its fiscal 2017, despite weak profit. Looking ahead, the company projects capacity growth in fiscal 2018. Following his twelve-day trip to Asia, President Donald Trump announced Monday the U.S. is putting North Korea back on a list of state sponsors of terrorism. Trump announced the move in comments ahead of a Cabinet meeting and said his administration would also be ramping up sanctions on North Korea.
comments powered by Disqus
Follow RTT